These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 17012902

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
    Creech CB, Frenck RW, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.
    Vaccine; 2017 Jan 05; 35(2):385-394. PubMed ID: 27866765
    [Abstract] [Full Text] [Related]

  • 24. Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8-fusion protein (Hla-MntC-SACOL0723) immunoconjugates.
    Ahmadi K, Aslani MM, Pouladfar G, Faezi S, Kalani M, Pourmand MR, Ghaedi T, Havaei SA, Mahdavi M.
    IUBMB Life; 2020 Feb 05; 72(2):226-236. PubMed ID: 31573748
    [Abstract] [Full Text] [Related]

  • 25. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.
    Safari Zanjani L, Shapouri R, Dezfulian M, Mahdavi M, Shafiee Ardestani M.
    World J Microbiol Biotechnol; 2019 Jun 11; 35(6):94. PubMed ID: 31187291
    [Abstract] [Full Text] [Related]

  • 26. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
    Shinefield HR.
    Vaccine; 2006 Apr 12; 24 Suppl 2():S2-65-9. PubMed ID: 16823932
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
    Fattom AI, Sarwar J, Basham L, Ennifar S, Naso R.
    Infect Immun; 1998 Oct 12; 66(10):4588-92. PubMed ID: 9746554
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
    Fattom AI, Sarwar J, Ortiz A, Naso R.
    Infect Immun; 1996 May 12; 64(5):1659-65. PubMed ID: 8613375
    [Abstract] [Full Text] [Related]

  • 31. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
    Cryz SJ, Lang AB, Sadoff JC, Germanier R, Fürer E.
    Infect Immun; 1987 Jul 12; 55(7):1547-51. PubMed ID: 3110065
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines.
    Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ.
    Vaccine; 2001 Apr 30; 19(23-24):3189-200. PubMed ID: 11312015
    [Abstract] [Full Text] [Related]

  • 35. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein.
    Michon F, Fusco PC, Minetti CA, Laude-Sharp M, Uitz C, Huang CH, D'Ambra AJ, Moore S, Remeta DP, Heron I, Blake MS.
    Vaccine; 1998 Nov 30; 16(18):1732-41. PubMed ID: 9778749
    [Abstract] [Full Text] [Related]

  • 36. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
    Rubinstein LJ, García-Ojeda PA, Michon F, Jennings HJ, Stein KE.
    Infect Immun; 1998 Nov 30; 66(11):5450-6. PubMed ID: 9784556
    [Abstract] [Full Text] [Related]

  • 37. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
    Devi SJ, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE.
    Infect Immun; 1997 Mar 30; 65(3):1045-52. PubMed ID: 9038314
    [Abstract] [Full Text] [Related]

  • 38. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T, Yu W, Wang Y, Hu T.
    Vaccine; 2015 Jun 22; 33(28):3208-14. PubMed ID: 25964170
    [Abstract] [Full Text] [Related]

  • 39. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Vaccine; 2000 Nov 22; 19(7-8):850-61. PubMed ID: 11115709
    [Abstract] [Full Text] [Related]

  • 40. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine.
    Wei D, Yu W, Hu C, Shen L, Hu T.
    Biotechnol Lett; 2018 Aug 22; 40(8):1263-1270. PubMed ID: 29802568
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.